Answers are grounded in this paper and cite their sources.
Reports survival outcomes and failure patterns in unresectable NSCLC, suggesting advancements in therapy.
PURPOSE: FLARE-RT tested personalized functional-lung-avoidance and response-adaptive radiotherapy intensification for unresectable non-small cell lung cancer (NSCLC) using FDG-PET/CT and SPECT/CT. We report mature outcomes and failure patterns. METHODS: 49 patients with AJCCv7 stage IIB-IIIB NSCLC enrolled on FLARE-RT (NCT02773238) from 2016-2021 and initiated chemoradiation. Patients with Week 3 FDG-PET response received 60Gy in 30 fractions. Patients with non-response received concomitant boosts Weeks 4-6 to residual metabolic disease of 74-90Gy total guided by FDG uptake. Overall survival (OS, primary endpoint) and progression free survival (PFS) were estimated via Kaplan-Meier. Locoregional progression (LRP) and distant metastasis (DM) cumulative incidence were estimated via Aalen-Johansen, with death and alternative progression pattern as competing risks. Predictors of treatment failure modes were identified through Fine-Gray regression. RESULTS: At 52.3 months median follow-up, 1-year and 2-year OS were 81.6% (95%CI:71.5-93.2%) and 54.2% (CI:41.8-70.4%), respectively; 1-year and 2-year PFS were 53.1% (CI:40.9-69.0%) and 40.5% (CI:28.8-57.0%), respectively. Cumulative incidence for 1-year and 2-year LRP was 12.2% (CI:4.9-23.2%) and 18.5% (CI:9.0-30.6%), respectively; 1-year and 2-year DM were 34.7% (CI:21.7-48.1%) and 43.1% (CI:28.9-56.5%), respectively. Higher pre-RT FDG-PET total lesion glycolysis (TLG) correlated with increased LRP (HR=1.87 [CI:1.41-2.49], p<0.001), whereas higher mid-RT TLG correlated with DM (HR=1.52 [CI:1.05-2.21], p=0.03). 25 of 49 patients received durvalumab and exhibited lower 1-year DM (20.0% vs. 54.2%, p=0.04) with equivocal 1-year LRP (20.0% vs. 4.2%, p=0.27). CONCLUSION: Biological image-guided FLARE-RT achieved durable locoregional control with consistent survival outcomes relative to RTOG0616 (60Gy arm) and RTOG1106 (adaptive arm). This informs biomarker-guided and risk-adaptive therapy for unresectable NSCLC.
No takes yet. Share an insight, caveat, or question.
Zeng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: